Mikiya Miyazato

Ghrelin : A multifunctional hormone in non-mammalian vertebrates

In mammals, ghrelin is a non-amidated peptide hormone, existing in both acylated and non-acylated forms, produced mainly from the X/A or ghrelin cells present in the mucosal layer of the stomach. Ghrelin is a natural ligand of the growth hormone (GH) secretagogue-receptor (GHS-R), and functions primarily as a GH-releasing hormone and an orexigen, as well as having several other biological actions. Among non-mammalian vertebrates, amino acid sequence of ghrelin has been reported in two species of cartilaginous fish, seven species of teleosts, two species of amphibians, one species of reptile and six species of birds. The structure and functions of ghrelin are highly conserved among vertebrates. This review presents a concise overview of ghrelin biology in non-mammalian vertebrates.

Identification of neuromedin S and its possible role in the mammalian circadian oscillator system

The discovery of neuropeptides has resulted in an increased understanding of novel regulatory mechanisms of certain physiological phenomena. Here we identify a novel neuropeptide of 36 amino‐acid residues in rat brain as an endogenous ligand for the orphan G protein‐coupled receptor FM‐4/TGR‐1, which was identified to date as the neuromedin U (NMU) receptor, and designate this peptide ‘neuromedin S (NMS)’ because it is specifically expressed in the suprachiasmatic nuclei (SCN) of the hypothalamus. NMS shares a C‐terminal core structure with NMU. The NMS precursor contains another novel peptide. NMS mRNA is highly expressed in the central nervous system, spleen and testis. In rat brain, NMS expression is restricted to the core of the SCN and has a diurnal peak under light/dark cycling, but remains stable under constant darkness. Intracerebroventricular administration of NMS in rats activates SCN neurons and induces nonphotic type phase shifts in the circadian rhythm of locomotor activity. These findings suggest that NMS in the SCN is implicated in the regulation of circadian rhythms through autocrine and/or paracrine actions.

Somatostatin suppresses ghrelin secretion from the rat stomach.

Ghrelin is an acylated peptide that stimulates food intake and the secretion of growth hormone. While ghrelin is predominantly synthesized in a subset of endocrine cells in the oxyntic gland of the human and rat stomach, the mechanism regulating ghrelin secretion remains unknown. Somatostatin, a peptide produced in the gastric oxyntic mucosa, is known to suppress secretion of several gastrointestinal peptides in a paracrine fashion. By double immunohistochemistry, we demonstrated that somatostatin-immunoreactive cells contact ghrelin-immunoreactive cells. A single intravenous injection of somatostatin reduced the systemic plasma concentration of ghrelin in rats. Continuous infusion of somatostatin into the gastric artery of the vascularly perfused rat stomach suppressed ghrelin secretion in both dose- and time-dependent manner. These findings indicate that ghrelin secretion from the stomach is regulated by gastric somatostatin.

Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart

Background— Mice lacking guanylyl cyclase-A (GC-A), a natriuretic peptide receptor, have pressure-independent cardiac hypertrophy. However, the mechanism underlying GC-A-mediated inhibition of cardiac hypertrophy remains to be elucidated. In the present report, we examined the role of regulator of G-protein signaling subtype 4 (RGS4), a GTPase activating protein for Gq and Gi, in the antihypertrophic effects of GC-A. Methods and Results— In cultured cardiac myocytes, treatment of atrial natriuretic peptide stimulated the binding of guanosine 3′,5′-cyclic monophosphate-dependent protein kinase (PKG) I-&agr; to RGS4, PKG-dependent phosphorylation of RGS4, and association of RGS4 and G&agr;q. In contrast, blockade of GC-A by an antagonist, HS-142-1, attenuated the phosphorylation of RGS4 and association of RGS4 and G&agr;q. Moreover, overexpressing a dominant negative form of RGS4 diminished the inhibitory effects of atrial natriuretic peptide on endothelin-1–stimulated inositol 1,4,5-triphosphate production, [3H]leucine incorporation, and atrial natriuretic peptide gene expression. Furthermore, expression and phosphorylation of RGS4 were significantly reduced in the hearts of GC-A knockout (GC-A-KO) mice compared with wild-type mice. For further investigation, we constructed cardiomyocyte-specific RGS4 transgenic mice and crossbred them with GC-A-KO mice. The cardiac RGS4 overexpression in GC-A-KO mice significantly reduced the ratio of heart to body weight (P<0.001), cardiomyocyte size (P<0.01), and ventricular calcineurin activity (P<0.05) to 80%, 76%, and 67% of nontransgenic GC-A-KO mice, respectively. It also significantly suppressed the augmented cardiac expression of hypertrophy-related genes in GC-A-KO mice. Conclusions— These results provide evidence that GC-A activates cardiac RGS4, which attenuates G&agr;q and its downstream hypertrophic signaling, and that RGS4 plays important roles in GC-A-mediated inhibition of cardiac hypertrophy.

Ghrelin and cardiovascular diseases

In 1999, a peptide from the stomach called ghrelin was discovered, which exerts potent growth hormone releasing powers. Subsequent studies revealed that it exerts a potent orexigenic action. In addition, the beneficial effects of ghrelin in cardiovascular diseases have been recently suggested. In humans as well as in animals, administration of ghrelin improves cardiac function and remodeling in chronic heart failure. In an animal model for myocardial infarction, ghrelin treatment early after coronary ligation effectively reduces fatal arrhythmia and, consequently, mortality, suggesting the potential therapeutic role of the peptide in acute myocardial infarction. Although how ghrelin may influence the cardiovascular system is not fully understood, the cardiovascular beneficial effects are mediated possibly through a combination of various actions, such as an increase in growth hormone level, an improvement in energy balance, direct actions to the cardiovascular cells, and regulation of the autonomic nervous activity. Of note, current experimental evidence suggests that ghrelin may act centrally to decrease sympathetic nervous system activity through peripheral afferent nerve. Thus, administration of ghrelin might become a unique new therapy for cardiovascular diseases.

Purification and properties of ghrelin from the intestine of the goldfish, Carassius auratus

In goldfish, intraperitoneal (IP) or intracerebroventricular (ICV) administration of synthetic ghrelin consisting of 12- or 19-amino-acid residues, deduced from its precursor cDNA, with an octanoic acid modification at the third N-terminal serine residue (Ser(3)), stimulates growth hormone release and food intake. However, native ghrelin generated from its precursor has not yet been identified in this species. Therefore, we purified ghrelin from the goldfish intestine using acid extraction, cation-exchange and reverse-phase high-performance liquid chromatography combined with immune-affinity purification. In order to confirm ghrelin activity in the fractions at each purification step, we examined the effect of each fraction on intracellular Ca(2+) mobilization in rat growth hormone secretagogue-receptor (GHS-R)-expressing cells. We characterized the goldfish ghrelin as 11 molecular forms consisting of 14-, 17-, 18- and 19-amino-acid residues with acylation at Ser(3), and the 17-residue form was predominant. We then synthesized 17-residue forms with octanoic acid modification (octanoyl ghrelin17) and without acylation (des-acyl ghrelin17) at Ser(3), and examined their biological activity. Octanoyl ghrelin17, but not des-acyl ghrelin17, increased the intracellular Ca(2+) concentration in rat GHS-R-expressing cells with a potency similar to those of synthetic ghrelin consisting of 12 residues (octanoyl ghrelin12) and octanoyl rat ghrelin. IP and ICV administration of octanoyl ghrelin17 and octanoyl ghrelin12, but not des-acyl ghrelin17, increased food intake in goldfish. The present findings indicate that native goldfish ghrelin consists of 11 molecular variants, the major form being a 17-residue peptide. This dominant form with acylation is implicated in the regulation of food intake in goldfish.

Current knowledge of the roles of ghrelin in regulating food intake and energy balance in birds

A decade has passed since the peptide hormone ghrelin was first discovered in rat stomach. During this period, ghrelin has been identified not only in other mammals but also in fish, amphibians, reptiles and birds, and its physiological functions have been widely investigated. Avian ghrelin was first identified in chickens in 2002 and to date, the amino acid sequences of six different avian ghrelin peptides have been reported. In mammals, ghrelin is the only known gut-derived hormone to stimulate food intake when administered centrally or peripherally. In studies on chickens and quail, however, ghrelin inhibits food intake when injected centrally, while the effects on feeding behavior elicited by ghrelin injected peripherally are equivocal. This review summarizes what is currently known about the regulation of food intake and energy balance by ghrelin in birds.

Recent advances in the phylogenetic study of ghrelin.

To understand fully the biology of ghrelin, it is important to know the evolutionary history of ghrelin and its receptor. Phylogenetic and comparative genomic studies of mammalian and non-mammalian vertebrates are a useful approach to that end. Ghrelin is a hormone that has apparently evaded natural selection during a long evolutionary history. Surely ghrelin plays crucial physiological roles in living animals. Phylogenetic studies reveal the nature and evolutionary history of this important signaling system.

Two functional growth hormone secretagogue receptor (ghrelin receptor) type 1a and 2a in goldfish, Carassius auratus.

Here we report the identification and characterization of ghrelin (GRLN) receptors in goldfish Carassius auratus. We identified four distinct mRNAs generated from four different genes. Those were roughly divided into two types, based on the number of amino acids and amino acid sequence similarity; one composed of 360-amino acids, which is similar to zebrafish GHS-R1a (showing 94-96% identity) and the other encodes a 366- or 367-amino acid protein, which demonstrated 95% identity to zebrafish GHS-R2a. We therefore designated these proteins as goldfish GHS-R1a type 1 (1a-1) and type 2 (1a-2) and GHS-R2a type 1 (2a-1) and type 2 (2a-2). GHS-R1a and 2a proteins share 74% sequence identity with each other. In functional analyses, three of these four receptors (except 2a-2 receptor), were activated by goldfish GRLN or GHS. The GRLN activity was inhibited by [D-Lys(3)] GHRP-6 but not by des-acyl goldfish GRLN. Expression levels of GHS-R1a mRNA were 2- to 50-folds higher than those of GHS-R2a, and GHS-R2a-2 mRNA expression was 1/25 of GHS-R2a-1. GHS-R1a-1 and 1a-2 mRNAs were mainly detected in the central nervous system (CNS), pituitary, liver, intestine and testis, whereas GHS-R2a-1 and 2a-2 mRNAs were predominantly expressed in the CNS, body kidney, ovary and testis. A 7-day fasting led to a decrease in GHS-R1a-1 mRNA expression in the vagal lobe, but stimulated GHS-R1a-2 mRNA in the liver, although no change was observed in GHS-R2a mRNAs. These results indicate that goldfish has four GHS-Ra that is divided into two types, 1a and 2a; and each receptor expression is separately regulated with GHS-R1a acts on energy metabolism.

Identification of the novel bioactive peptides dRYamide-1 and dRYamide-2, ligands for a neuropeptide Y-like receptor in Drosophila

A number of bioactive peptides are involved in regulating a wide range of animal behaviors, including food consumption. Vertebrate neuropeptide Y (NPY) is a potent stimulator of appetitive behavior. Recently, Drosophila neuropeptide F (dNPF) and short NPF (sNPF), the Drosophila homologs of the vertebrate NPY, were identified to characterize the functions of NPFs in the feeding behaviors of this insect. Dm-NPFR1 and NPFR76F are the receptors for dNPF and sNPF, respectively; both receptors are G protein-coupled receptors (GPCRs). Another GPCR (CG5811; NepYR) was indentified in Drosophila as a neuropeptide Y-like receptor. Here, we identified 2 ligands of CG5811, dRYamide-1 and dRYamide-2. Both peptides are derived from the same precursor (CG40733) and have no significant structural similarities to known bioactive peptides. The C-terminal sequence RYamide of dRYamides is identical to that of NPY family peptides; on the other hand, dNPF and sNPF have C-terminal RFamide. When administered to blowflies, dRYamide-1 suppressed feeding motivation. We propose that dRYamides are related to the NPY family in vertebrates, similar to dNPF and sNPF.